Effects of cladribine on cognitive and physical disability in MS: A Retrospective Real-World Study
European Neurology · 14.11.2026
DOI: 10.1159/ene/acsag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Neurology, online erschienen am 14.11.2026. Verfasst von Serkan Ozakbas und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cladribine tablets are an established oral immune reconstitution therapy for relapsing multiple sclerosis, with proven clinical and radiological efficacy. However, evidence regarding their effects on cognitive and physical outcomes in real-world settings remains limited.
Objective
To assess the clinical, radiological, cognitive, and physical outcomes of cladribine treatment in people with Multiple Sclerosis (pwMS) over a follow-up of up to two years in a real-world cohort.
Methods
A total of 173 patients with multiple sclerosis (pwMS) received cladribine treatment and were subsequently followed over time. Clinical data, including relapse rate, EDSS, and MRI findings, were collected annually. Cognitive (BICAMS: Brief International Cognitive Assessment for MS) and physical performance (T25FW: Timed-25-Foot Walking Test, N-HPT: Nine-Hole Peg Test) data of a subgroup of participants were collected at baseline, year 1, and year 2.
Results
The mean age was 36.75 ± 11.44, and the mean disease duration was 8.33 ± 6.85 years. Over a two-year follow-up, 94.8% of patients remained relapse-free, and MRI activity was absent in 96.5%. Significant improvements were observed in all BICAMS subtests (p < 0.05). While T25FW increased over years (p: 0.017), NHPT showed a similar trajectory (p>0.05).
Conclusion
Cladribine demonstrated high efficacy in suppressing clinical and radiological activity while supporting cognitive stability.
Zitieren
APA
Ozakbas, S., Kaya, E., Ozdogar, A. T., Simsek, Y., & Zengin, E. S. (2026). Effects of cladribine on cognitive and physical disability in MS: A Retrospective Real-World Study. European Neurology. https://doi.org/10.1159/ene/acsag017
Vancouver
Ozakbas S, Kaya E, Ozdogar AT, Simsek Y, Zengin ES. Effects of cladribine on cognitive and physical disability in MS: A Retrospective Real-World Study. European Neurology. 2026. doi:10.1159/ene/acsag017
BibTeX
@article{Ozakbas2026,
author = {Ozakbas, Serkan and Kaya, Ergi and Ozdogar, Asiye Tuba and Simsek, Yasemin and Zengin, Ela Simay},
title = {Effects of cladribine on cognitive and physical disability in MS: A Retrospective Real-World Study},
journal = {European Neurology},
year = {2026},
doi = {10.1159/ene/acsag017}
}
EUVIMED